secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2026-07-02T10:20:28+00:00
Accession:  0001104659-26-080058
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio Therapeutics prices $15M registered direct offering of 4.38M shares at $3.43/share
--------------------------------------------------------------------------------

- Offering of 4,380,313 shares of common stock at $3.43 per share for gross proceeds of ~$15M.
- Two new institutional investors and a large existing shareholder participated; expected close July 6, 2026.
- Net proceeds to fund Phase 1 clinical development of ELI-002 7P in metastatic PDAC and pipeline/platform.
- Titan Partners (lead) and B. Riley Securities (co-placement agent) acted as placement agents.
- Offering made under effective shelf registration statement (File No. 333-293861).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000110465926080058/0001104659-26-080058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000110465926080058/tm2619637d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-080058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer